Enterprise Value
1.209B
Cash
202.6M
Avg Qtr Burn
-20.16M
Short % of Float
12.08%
Insider Ownership
1.70%
Institutional Own.
60.70%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
XPHOZAH (Tenapanor) (Phosphate Absorption Inhibitor) Details Electrolyte disorder, Hyperphosphatemia, Kidney disease, Chronic kidney disease | Approved Quarterly sales | |
Tenapanor (Ibsrela) (NHE3 sodium transport inhibitor) Details Constipation, Irritable bowel syndrome | Approved Quarterly sales | |
RDX013 Details Hyperkalemia | Phase 2 Update |